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Abstract 
 
Background: Endometrial cancer survivors comprise a high-risk group for obesity-related 
comorbidities. Healthy eating and physical activity can lead to better health and well-being 
but this population may experience difficulties adopting healthy lifestyle practices. 
Personalised behaviour change programmes that are feasible, acceptable, and cost-effective 
are needed. The aim of this trial is to pilot a manualised programme about healthy eating and 
physical activity.   
 
Methods/Design: This is a phase II, individually randomized, parallel, controlled, two-site, 
pilot clinical trial. Adult endometrial cancer survivors (n=64) who have been diagnosed with 
endometrial cancer within the previous 3 years and are not on active treatment will be invited 
to participate. Participants will be assigned in a 1:1 ratio through minimisation to either an 
eight-week, group-based, behaviour-change programme with weekly 90-min sessions about 
healthy eating and physical activity or usual care. The intervention will focus on self-
monitoring, goal setting, and rewards. Follow-up assessments will be conducted at 8 and 24 
weeks from the baseline assessment. Primary feasibility outcomes will include rates of 
recruitment, adherence, and retention. 
 
Discussion: The study results will inform the development of a definitive randomised 
controlled trial to test if the programme can improve the health and quality of life of this 
population. It will also provide guidance on costing the intervention and the health care 
resource use in this population.  
 
Trial Registration: ClinicalTrials.gov identifier: NCT02433080, April 20, 2015 
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Background 
 
Endometrial cancer is the most common gynaecological cancer in developed countries with 
more than 75% of the patients surviving for at least five years. [1]. Low physical activity, 
poor diet and obesity are risk factors for the development of endometrial cancer [2]. These 
factors may also be linked with quality of life after cancer treatment [3]. While the evidence 
on the impact of post-diagnosis health behaviours on endometrial cancer survival is still 
unclear [4], evidence from other cancer sites suggests that similar factors that affect cancer 
development may also influence survival [5-8]. However, adherence to lifestyle 
recommendations [9] is limited [10], putting survivors at high risk for other chronic diseases. 
 
Cancer survivors often report making health behaviour changes [11]. As survivors might be 
motivated to practice health-protecting behaviours, a cancer diagnosis has been posited to be 
a “teachable moment”. However, survivors rarely initiate lifestyle behavioural changes 
evidence of such changes is limited [12-15]. Behaviour change interventions capitalising on 
the “teachable moment” might therefore be more effective than those targeting the general 
population [16, 17]. While the optimal timing of the teachable moment has not been defined, 
the post-treatment period seems optimal for provision of healthy eating interventions [18]. 
Promotion of physical activity might be independent of timing [18] but ten physical activity 
trials have accrued survivors within a median of 3.1 years after their diagnosis [19]. 
However, willingness to participate in health behaviour trials reduces with time since 
diagnosis in long-term cancer survivors (>5 years since diagnosis) [20]. Qualitative data in 
endometrial cancer survivors also support the post-treatment period as the most appropriate 
time to intervene [21]. While on a vital position to do so, health professionals do not tend to 
provide lifestyle advice [22], particularly given time constraints. Therefore, feasible and 
effective interventions are needed to promote implementation of lifestyle recommendations. 
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Rationale 
 
Theory-based behaviour change interventions suggest that improving diet and physical 
activity is safe, acceptable, and feasible with promising effects on both psychological and 
physiological outcomes, including quality of life [23-26]. In the USA, the two interventions 
in endometrial cancer survivors have also shown sustained changes in behavioural outcomes 
and indicated potential changes in quality of life domains [27, 28]. Quality of life and its 
components are valuable outcome measures, as they are associated with disease status and 
presence of co-morbidities and they are core components of strategic needs assessments for 
cancer survivors [29]. However, the majority of these interventions lasted for six months or 
more and were resource intensive (e.g. personalised materials, highly trained coaches). 
Although cost-effective analyses are scarce [30], such intensity or duration may render them 
inappropriate for wide dissemination. Furthermore, these interventions may not be fully 
applicable to other cancer groups given the in between differences in long-term treatment 
effects. Qualitative work with endometrial cancer survivors suggests they highly desire 
information regarding specific late-treatment effects and advice on healthy eating and 
physical activity post-treatment and in person [21]. Finally, similarities in effectiveness of 
programs delivered across developed countries are expected. However, both the health 
systems and the causes of obesity differ between the USA and the UK [31]. Despite the 
common focus of such programs on healthy eating and physical activity, these differences 
might make a program developed in one context less applicable in the other. 
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There is, therefore, a need to develop effective behaviour change interventions for 
endometrial cancer survivors that meet an identified need, and which could be implemented 
in the cancer care pathway both in terms of length of programme and resource use. Pre-
existing programmes for improving diet and physical activity in the general population, 
which have demonstrated usability within the NHS, may be an untapped resource. These 
programmes could be adapted to take into account the specific needs and experiences of 
endometrial cancer survivors, while retaining the core components that have made them 
effective in other populations. 
 
Aim 
 
The aim of this pilot study is to assess the feasibility of a manualised healthy eating and 
physical activity programme in endometrial cancer survivors post active treatment.  
 
The main research question is: “Is it feasible to design a randomised controlled trial that will 
assess if the Shape-Up following cancer treatment programme is more effective than usual 
care in improving the health-related quality of life of endometrial cancer survivors?”.  
 
Study objectives 
 
Primary research objective 
 
The primary research objective is to assess the feasibility of the overall trial procedures. 
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Secondary research objectives 
 
Secondary research objectives will include: (1) to obtain variance estimates for clinical 
outcome measures to be used in the large-scale RCT. These will inform the measurement of 
the primary outcome for the larger trial and, subsequently, the sample size calculation; (2) to 
assess willingness of the clinical staff to recruit participants; (3) to assess willingness of 
eligible participants to be randomised; (4) to examine potential adverse effects of the 
intervention; (5) to perform a basic economic analysis with the aim to inform the larger trial; 
(6) to assess reasons for loss to follow up; and (7) to access the overall acceptability of the 
intervention. 
 
Methods 
 
Preliminary work 
 
The intervention is based on the Shape-Up: A lifestyle programme to manage your weight, 
eight-week weight management programme, which aims to help service users learn new 
behaviours and manage their weight [32, 33]. This manualised healthy lifestyle programme is 
based on social cognitive theory [34] and control theory [35] focusing on self-control, self-
efficacy, and behavioural relapse prevention. The intervention is under the tier 2 weight 
management services [36] and in line with NICE guidance on lifestyle weight management 
services [17] and individual approaches in behaviour change [37]. Currently, a version of 
original program is successfully being run in two London boroughs as part of the local joint 
strategic needs assessment [38]. 
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The programme has been renamed (Shape-Up following cancer treatment: a self-help guide 
to eating well and being active) and the intervention development process will be separately 
reported. In brief, the tailored version is focused on healthy eating and physical activity rather 
than weight loss based on the lack of strong evidence for the benefits of intentional weight 
loss in cancer survival outcomes. A stronger focus on resistance, flexibility, and balance 
exercises has been be added, given their benefits in cancer survivors [39, 40]. Furthermore, 
specific recommendations about radiotherapy and chemotherapy treatment effects have been 
added to the booklet, such as avoiding high-fat foods or choosing cooked vegetables.  
 
Study Design 
 
The DEUS pilot trial is an eight-week, two-arm, individually randomised, controlled pilot 
trial comparing the use of the Shape-Up following cancer treatment programme to usual care. 
According to MRC guidance for complex interventions [41], this is a Phase 2 feasibility 
study. Randomisation will be performed with minimisation using an 1:1 allocation. 
 
Study setting 
 
Participants will be recruited from two major academic hospitals in London with sufficient 
caseload of endometrial cancer patients; University College London Hospitals NHS 
Foundation Trust, and Barts Health NHS Foundation Trust. The intervention program will be 
delivered at the University College Hospital Macmillan Cancer Support and Information 
Centre, located in central London. 
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Selection of Subjects 
 
Inclusion criteria 
 
Women aged >18 years (no upper age limit) who have been diagnosed with endometrial 
cancer (ICD C54.1) within the previous 36 months will be eligible to take part in the study. 
They must also be able to understand spoken and written English. The cut-off of 36 months 
was chosen to account for the duration of treatment and allow for a sufficient pool of 
survivors for recruitment so that the presence of the teachable moment and the elimination of 
early major treatment effects can be balanced.  
 
Exclusion criteria  
 
Women who meet at least one of the following criteria will be excluded: (1) diagnosed with 
stage IVB (metastatic) endometrial cancer (any metastasis beyond the pelvis); (2) undergoing 
active anti-cancer, and/or palliative treatment; (3) having a second primary cancer; (4) 
lacking mental capacity to decide to take part in the study and to participate in it (based upon 
the clinical team’s judgement in accordance with the Mental Capacity Act 2005 Code of 
Practice 2007); (5) having severe depression (upon consultant’s judgement based on the 
DSM-IV criteria); (6) unavailable for longitudinal follow-up assessments; (7) having 
participated in a professionally delivered weight loss or exercise program during the previous 
six months; (8) having a WHO performance score 3-4 [42]. These criteria comply with all but 
the disability category in the NICE Equality Impact Assessment for lifestyle weight 
management services [17]. 
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Interventions 
 
Active intervention 
 
A researcher in nutrition and dietetics (DAK), trained by Weight Concern, who has clinical 
experience with cancer survivors, will facilitate the Shape-Up following cancer treatment 
sessions following the standardised and scripted manual. An extra trained provider will attend 
the intervention meetings to aid with facilitation but will not participate in the discussion. 
S/he will deliver the intervention in case of unpredictable circumstances. In addition to usual 
care, they will be assigned to groups of eight on a first-come first-served basis to avoid delays 
in delivering the intervention. These groups will meet for weekly 90-minute sessions for 
eight weeks, 
 
The tailored version’s primary focus is on strategies for improving healthy eating and 
physical activity and brief advice on weight management for those who would like it. 
Behavioural techniques include self-monitoring of behaviour with the use of food and 
physical activity diaries, behavioural goal setting, action planning, graded tasks, problem 
solving, self-reward, and review of behavioural goals. It also provides information about the 
health consequences and emotional consequences of making dietary and activity changes, 
pros and cons, behavioural practice, habit formation, reducing exposure to cues for the 
behaviour, behaviour substitution, distraction, social support (unspecified), demonstration of 
behaviour (for resistance exercises), instructions on how to perform the behaviour (for 
resistance exercises), and reframing [43]. 
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The course structure and content are shown in Table 1. The format of the intervention is self-
help and peer education. Each week, participants will be asked to read part of the manual in 
preparation for the following week’s new topic. Participants should set their first SMART 
goal (Specific, Measureable, Attainable, Relevant, Time-bound) for regular eating after the 
second session, and the first SMART goal for physical activity after the third session. After 
each of the subsequent sessions, participants should set at least one eating and one physical 
activity SMART goal. 
 
Those who miss sessions will receive standardized e-mails or mail with the content of the 
session. They will also be asked not to discuss the intervention with fellow patients in an 
attempt to minimize contamination and avoid leakage of intervention details between patients 
in the study arms. 
 
Control group 
 
Participants in the control group will be offered usual care. Quantifying usual care is 
challenging, but our preliminary qualitative study suggested that lifestyle advice is limited in 
the current clinical setting [21]. During the trial, participants will only be contacted for the 
assessments. After the final follow-up, the researcher will have a five-minute discussion with 
them using a standard statement focusing on the link between lifestyle and health 
consequences and targeting their motivation to improve their health. At that point, they will 
also receive the “Healthy living after cancer” booklet; a brief self-help manual produced by 
the World Cancer Research Fund [44].  
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Outcome measures 
 
Primary outcome measures 
  
The primary outcome measures for the pilot trial are: 
1. The recruitment rate 
2. The adherence rate (attendance of the sessions) 
3. The retention rate (complete follow-up) 
 
The main criterion to judge the pilot study successful and a large-scale RCT feasible using 
the recruitment measure is recruiting (consenting) 30% of the eligible participants (32 
participants per 110 estimated to be eligible in each centre during the 6 month recruitment). 
This target seems reasonable based on our previous experience and similar rates indicated in 
the literature [45, 46]. 
 
Secondary outcome measures 
 
1. Clinical outcomes to be used in the large RCT: 
I. Health-related quality of life 
II. Diet quality 
III. Physical activity  
IV. Hand-grip strength 
V. Weight 
VI. Body composition  
VII. Shape-Up evaluation questionnaire 
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VIII. Health care services use 
The primary measure to be used in the large-scale RCT is projected to be a change in global 
quality of life as measured by the EORTC Quality of Life Questionnaire (QLQ- C-30). 
However, the choice of additional primary outcomes will be finalised after taking into 
account the results of the feasibility study. 
2. Willingness of clinical staff to recruit participants will be assessed with a short one-
to-one interview with the clinicians at the beginning of the third month of recruitment.   
3. The number and type of potential adverse effects of the intervention will be recorded 
during the intervention and at the follow-up interview (e.g. gastro-intestinal 
complaints from a change in diet). 
4. Costs relevant to recruitment, screening, implementation, and follow-up will be 
calculated. We will also measure retrospectively health care resource use and cost 
them at national rates. 
5. Reasons for none participation and loss to follow up will be tracked for each 
participant lost and merged in similar categories. 
6. At 8 and 24 weeks follow-up, a purposive sample (30%) of participants in each arm 
will be interviewed to assess their experience of participating in the trial, the 
acceptability of the intervention and the materials, and their overall experience of the 
program, including potential facilitators or barriers to adherence. All participants who 
may dropout will also be approached for an interview. These data will help with the 
refinement of the intervention. 
 
Participant Timeline 
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Figure 1 demonstrates the flow chart of the study. Table 2 shows the assessments at each time 
point. 
 
Sample size 
 
Although this is a feasibility study, a sample size has been specified for examining the 
recruitment rate, using the A’Hern’s approach for one-stage phase II trials [47]. Regarding 
recruitment, a success rate of approximately 30% or more would be desirable, for the trial to 
be considered feasible. A success rate of 15% or less would be unacceptable. The trial will 
test the null hypothesis H0 that recruitment is ≤15% against the alternative hypothesis H1 that 
recruitment is ≥30%. With a 5% level of significance and 90% power, 64 participants are 
needed so that we can estimate whether the percentage of participants with successful 
recruitment is ≤15% or ≥30%. If we can recruit 15, or more, participants, we can reject the 
null hypothesis.  
 
A trial of 64 (32 per arm) will be sufficient to test the above hypothesis and allow decisions 
to proceed to a Phase III trial. It will also allow for rich feedback from the participants to be 
used for the optimisation of the procedures and the materials. Lastly, it will allow a certain 
degree of precision in calculating standard deviations for the secondary outcomes that will be 
the key design parameters for the main study [48].  
 
Recruitment 
 
Potential participants will be recruited from outpatient clinics at the two hospitals. They will 
be identified and approached by a member of the clinical team. Bright colour reminders will 
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be attached at the cover of the patient notes before their appointment to enhance consultants’ 
engagement with recruitment. After initial screening from the clinician and if the patient is 
willing to hear about the study, following verbal consent, they will be introduced to the 
researcher attending the clinic for final screening and a detailed discussion of the study. All 
participants will need to consent for themselves following standard procedures. We expect to 
recruit on average 1.07 participants per week per hospital during the 30-week recruitment 
period to reach our target. 
 
The clinical teams in the two hospitals will also identify potential participants that have been 
treated in the two recruitment sites but have been followed up at local sites. Following GP’s 
verification that the participants are alive, invitation letters signed by the consultant will be 
sent to these women together with the participant information sheet, an opt-in form, the 
barriers to participation survey [49], and a business reply envelope. 
 
 
Assignment of interventions 
 
Sequence generation 
 
Consented participants will be individually randomised with a 1:1 allocation to receive either 
the intervention or usual care through minimisation [50]. The two stratified variables are age 
(cut-off: 61 years) and obesity (BMI cut-off: 30kg/m2), as these are strong prognostic factors 
of all clinical outcome measures. The age cut-off was chosen as this is the median age of 
diagnosis for endometrial cancer [51] and the BMI cut-off is the WHO cut-off to classify 
obesity. 
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The allocated treatment will be determined using MinimPY software run by RJB. Initially, 
the first participant will be randomly allocated. For each participant following, allocation will 
be based on the imbalance scores, calculated as a function of current allocations after a 
hypothetical allocation of the new participant in each study arm. The new participant will be 
allocated to the arm with the least imbalance score [52]. A 20% random element will be 
included in the algorithm [50].  
 
Allocation concealment mechanism 
 
 The researcher (RJB) who generates the allocation sequence will keep the sequentially 
numbered opaque sealed envelopes. The rest of the team will have no physical access to 
them. The researcher will maintain no contact with the rest of the group about the allocation 
concealment until enough participants are allocated for a Shape-Up following cancer 
treatment group to run. 
 
Implementation 
 
Following the baseline assessment, DAK will feed back to RJB the BMI and the age of the 
recruited participant in a randomisation form in a sealed opaque envelope. The latter will run 
the algorithm and allocate the participant. This process will continue until enough 
participants are allocated in both groups to run a Shape-Up following cancer treatment group. 
Apart from RJB, all research team members will be blinded to group allocation until a group 
can be run (e.g. the first 16 participants have been randomised). At that point, participants 
will also be notified in which group they have been allocated.  
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Blinding 
 
Due to the nature of the intervention, neither participants nor the researchers delivering the 
intervention can be blinded. The independent trained assessor for the 8-week follow-up will 
be blinded to treatment allocation, requesting from the participants not to disclose their 
allocation treatment. The assessor of the 24-week follow-up (DAK) will not be blinded given 
resource constraints. 
 
Data collection, management, and analysis 
 
Data collection methods 
 
Participants will visit the laboratory for three 90-minute one-to-one assessments. They will 
complete the widely used, reliable, and validated European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) [53] and Endometrial Cancer 
Module (QLQ-EN24) [54]. We will use the Stanford 7-Day Physical Activity Recall [55], a 
15-min interview-based tool to assess physical activity, which has shown acceptable 
reliability and validity [56] and is responsive to change.  
 
Dietary intake will be assessed with one weekday 24-hour dietary recall using the ASA24 
web-based tool [57]. Nutrition and statistical software will be used to calculate how well their 
diet fits to recommended healthy eating patterns. Our previous piloting of the assessment 
indicated acceptability and feasibility. Diet quality will be calculated by the Alternative 
Healthy Eating Index (AHEI) score, assessing how well diet fits to recommended healthy 
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eating patterns and being a strong predictor of survival [58]. An updated version of the DINE 
questionnaire [59], together with questions about fruits, and vegetables will supplement the 
24-hour dietary recall data. 
 
Weight to the nearest 0.1kg and body composition will be assessed using MC980 multi-
frequency segmental body composition analyser. Using standardised protocols, standing 
height will be assessed to the nearest 0.1cm and handgrip strength using a handgrip 
dynamometer. Waist circumference will be measured to the nearest 0.1cm [60]. Blood 
pressure will be measured using an automated sphygmomanometer with the participant 
seated comfortably for five minutes before measurement and the arm supported at the level of 
the heart. All measurements will be taken twice and averaged for analysis. Participants will 
also complete six socio-demographic questions. Researchers will be receiving standardised 
training with all measurements. 
 
Participants will also complete at all time points the Shape-Up questionnaire; ten items in a 5-
likert scale (from “Strongly disagree” to “Strongly agree”) that reflect the overall goals of the 
programme (e.g. I am in control of my food portion sizes, I can set effective eating and 
activity goals and work towards them). At the end of the program, the intervention-arm 
participants will be given an 18-item evaluation form [61] to complete at home and return by 
post. To assess contamination, the control arm will complete at the 24-week follow-up two 
more questions assessing the input about diet and physical activity they received from 
external sources. At the last follow-up, all participants will also complete a health care 
resource use 6-item questionnaire [62]. Quality-of-life adjusted years (QALYs) will be 
assessed with the validated 6-item EQ5D-3L [63].  
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After they have taken enough time to decide about their participation, individuals will be 
asked their reason(s) for none participation [49]. The same questions and prompts will be 
asked of participants who decide to withdraw from the study. Participants may withdraw 
from the study for any reason at any time. However, we will make every reasonable effort to 
follow the participants for the entire study period. If a follow-up appointment in the 
laboratory is not possible after three consecutive contacting attempts, a researcher will 
request to visit the participants at home for the interview or undertake this by telephone. 
Participants will not be aware of this option beforehand to maximise the chances for having 
the physical measurements. 
 
Data management 
 
This study has been registered for Data Protection at UCL Records Office (Reference: 
Z6364106/2014/12/14). Standard procedures following Data Protection Act 1998, the NHS 
Code of Confidentiality, and Good Clinical Practice will be implemented throughout the 
study. 
 
Statistical methods 
 
In addition to recruitment rate, the study is also examining adherence rate and retention rate 
(complete follow-up). Adherence is defined as the proportion of engaged participants 
attending at least one of the last three sessions of the intervention. Engaged participants are 
those who have attended at least two sessions of the intervention. Best practice guidance 
suggests that programmes should be commissioned if at least 60% of participants are likely to 
adhere [36]. A success rate approximately of 85% or more would be desirable. That means 
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that 85% or more of the engaged participants in the intervention group will attend at least one 
of the last three sessions of the intervention. A success rate of 60% or less would be 
unacceptable. The trial will test the null hypothesis H0 that adherence is ≤60% against the 
alternative hypothesis H1 that adherence is ≥85%. With a 5% level of significance and 90% 
power, 27 participants are needed so that we can estimate whether the percentage of 
participants with successful adherence is ≤60% or ≥85%. If 21, or more, participants have a 
successful adherence, we can reject the null hypothesis.  
 
Regarding retention (attendance of both follow-up sessions) rate, a success rate 
approximately of 75% or more would be desirable. A success rate of 60% or less would be 
unacceptable. The trial will test the null hypothesis H0 that complete follow-up is ≤60% 
against the alternative hypothesis H1 that complete follow-up is ≥75%. With a 5% level of 
significance and 80% power, 62 participants are needed so that we can estimate whether the 
percentage of participants with complete follow-up is ≤60% or ≥75%. If 44, or more, 
participants have a complete follow-up, we can reject the null hypothesis.  
Recruitment, adherence, and retention rates will be reported as proportions with 95% CIs. 
The target lower 95% confidence limit for the following outcomes are 15% or more, 60% or 
more, and 60% or more for recruitment, adherence, and retention, respectively. 
 
Continuous variables will be reported by descriptive statistics (non-missing sample size, 
mean, standard deviation, median, maximum and minimum). Categorical variables will be 
summarised using frequencies and percentages. Analysis of covariance (ANCOVA) will be 
used to compare the intervention arm against the control arm in an exploratory way, as the 
study is not powered to detect differences. All participant data will be analysed using the 
intention-to-treat strategy [64]. Adjustment for BMI and age will be performed with linear 
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regression in continuous outcomes and logistic regression in binary outcomes. Missing 
outcome data will be imputed using multiple imputations. Reasons for missing data will be 
documented and missing data will be quantified. The Statistical Package for Social Sciences 
(SPSS, Chicago, IL) version 21 will be used for the whole data analysis. Adverse events will 
be reported descriptively. The level of statistical significance will be set at 5% for the 
primary outcome measures. We will also calculate intra-class correlation coefficients (ICCs) 
to measure clustering within groups and k coefficient of variation between groups. 
 
Qualitative data will be analysed using thematic analysis. Two interview transcripts will be 
independently coded by two researchers. These lists will be discussed and amended between 
researchers upon agreement until relevant themes are identified. DAK will insert the code 
lists into NVivo software version 10 (QSR International Pty Ltd, 2014). NVivo version 10 
(QSR International Pty Ltd, 2014). Two random transcripts will be recoded by an 
independent researcher to ensure consistency.  
 
Monitoring 
 
Data monitoring 
 
Given the short length of the intervention, the low risk of harm (see below) and the short 
follow-up of the intervention, an external Data Monitoring Committee will not be needed and 
an interim analysis will not be performed. Nonetheless, the researchers recruiting, 
implementing, and assessing the intervention will monthly update the research team about the 
study progress.  
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Harms 
 
Shape-Up following cancer treatment is a very low intensity intervention that should be 
suitable for most people with health conditions, such as diabetes, heart failure, and high blood 
pressure. Observed changes are unlikely to be associated with unintended or adverse effects 
[17]. The proposed modifications to lifestyle i.e. dietary and physical activity changes are in 
accordance with published guidelines for cancer survivors [9]. All potential adverse effects 
and unintended effects of the intervention will be reported.  
 
Auditing 
 
The sessions will be audiotaped and the recording will be coded against the Shape-Up 
following cancer treatment Facilitators manual for assessing intervention delivery and 
treatment receipt by a researcher experienced in health psychology and behaviour change 
[65]. The group facilitator (DAK) will also audio-record a short debriefing after each session. 
RJB will randomly perform undisclosed site visits in two assessments and one intervention 
session to assess protocol fidelity. The Shape-Up evaluation form, which includes a self-
assessment of the gained skills and an evaluation of the facilitator, will supplement fidelity 
assessment. Results will inform improvements in protocol fidelity.  
 
Ethics and dissemination 
 
Research ethics approval 
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The study protocol and documents have been reviewed and approved by the relevant sponsor 
and National Research Ethics Service Committee London - City Road & Hampstead 
(Reference: 15/LO/0154). 
 
Protocol amendments 
 
Potential protocol modifications will be formally approved by the REC before being 
implemented. The amendments will be communicated to the trial registries and outlined at 
the study dissemination.  
 
Post-trial care 
 
Archiving 
 
Study-related documents will be archived at UCL and each participating site at the end of the 
study for twenty years and in line with all relevant legal and statutory requirements.  
 
Dissemination policy 
 
The period for study dissemination will be kept to the minimum possible. The primary papers 
will report the primary outcome measures. The results will be disseminated regardless of the 
magnitude or direction of effect. All investigators will be authors of future publications with 
authorship eligibility to follow international guidelines [66]. The study results will also be 
disseminated to the clinical teams in the participating centres, and the participants. A 
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completely de-identified dataset will be disseminated to a relevant data archive for sharing 
purposes no later than three years after the study closeout. 
 
Roles and responsibilities 
 
Trial Management Group 
 
DAK will be responsible for the daily monitoring and management reporting directly to AL. 
AL has overall responsibility for the project. The two study site CIs (AL, RM) will oversee 
the identification of potential participants. RJB, and TMK will provide expert advice during 
the study and with the analysis and interpretation of the results. Prof. Steve Morris will 
provide advice regarding the health economic aspects. RJB will be responsible for 
intervention assignment, and auditing. 
 
Trial Steering Committee 
 
An external Trial Steering Committee that will meet at regular intervals during the study will 
oversee the trial,The committee chaired by Prof. Allan Hackshaw will include two other 
independent members,, the two site PIs (AL, RM), the trial co-investigators, and a lay 
representative. 
 
Discussion  
 
In the UK, only a few studies have demonstrated the feasibility of interventions for lifestyle 
behaviour change in cancer survivors [67, 68]. None of them, however, has involved the 
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growing population of endometrial cancer survivors. This feasibility trial will inform a larger 
lifestyle trial in cancer survivors to test if the program can help survivors to improve their 
quality of life. The outcome of this pilot study will be translated as (a) feasible study that 
should be continued without modifications; (b) feasible study with close monitoring that 
should be continued without modifications; (c) feasible study with modifications in the 
protocol; or (d) non-feasible study. The study has the potential not only to help cancer 
survivors improve their well-being but also to help NHS reduce its cost by potential reduction 
of the use of its services as survivors will lead a healthier lifestyle. 
 
The current intervention is in accordance with the National Cancer Survivorship Initiative, 
which envisages a sustainable personalised lifestyle support for cancer survivors with them 
playing an active part in the decision-making in addition to research on patient-reported 
outcomes [69]. If proven effective, we hope that Shape-Up following cancer treatment will 
be disseminated nationally as a low-cost, self-help, group program. The manualised format 
and the facilitator’s guide allow for standardised training for facilitators that could be non-
health care professionals, accurate replication, and evaluation across settings.  
 
Trial status 
 
The trial is currently recruiting participants. 
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